For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 / Ipamorelin Stack vs PEG-MGF

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 / Ipamorelin StackPEG-MGF
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combinationPEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF
EvidenceFDA-approvedPreclinical only
Dosing range100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split)
AdministrationSubcutaneous injection (both compounds), Administered together in the same injectionSubcutaneous injection (preferred for systemic distribution), Intramuscular injection
Key side effectsWater retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling
Cited sources2 references2 references

Key differences

  • Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while PEG-MGF is preclinical only.
  • Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
  • Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); PEG-MGF is 2x weekly (Monday/Thursday or similar split).

How each works

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

PEG-MGF

PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.

Read the full CJC-1295 / Ipamorelin Stack profileRead the full PEG-MGF profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.